PMID- 12544717
OWN - NLM
STAT- MEDLINE
DCOM- 20030515
LR  - 20191210
IS  - 0954-6928 (Print)
IS  - 0954-6928 (Linking)
VI  - 13
IP  - 8
DP  - 2002 Dec
TI  - Endogenous heparin--a protective marker in patients with myocardial infarction.
PG  - 423-6
AB  - BACKGROUND: In patients with myocardial infarction and initial high serum levels 
      of immunoglobulin E (IgE), lower mortality and a smaller quantity of 
      complications were observed. The aim of this study was to evaluate whether there 
      was a relationship between IgE serum levels and plasma concentration of 
      endogenous heparin in patients with myocardial infarction. Furthermore, we 
      attempted to analyse whether there was relationship between endogenous heparin 
      plasma concentrations and the specific markers (thrombin-anti-thrombin 
      \TAT\complexes) for thrombinogenesis. METHODS: Thirty-five healthy individuals 
      and 64 patients with recent myocardial infarction (MI), aged 37-70 years were 
      enrolled in the study. Patients with MI who had suffered cardiac arrest and 
      cardiogenic shock before admission to hospital, or had inflammatory diseases or a 
      negative allergic history were excluded. Serum IgE concentrations (UniCAP), TAT 
      complexes in plasma (ELISA, Behring) and endogenous heparin plasma levels 
      (Coatest Heparin) were measured at the time of admission and before treatment. 
      RESULTS: There were striking differences between the heparin concentrations in 
      patients with MI and the control group ( p< 0.0001). Higher levels of IgE were 
      strongly correlated with higher concentrations of endogenous heparin ( r= 0.80, p 
      < 0.001). Strong statistically significant negative correlations between higher 
      endogenous heparin concentrations and TAT complex levels were also found (r = 
      -0.57, p < 0.001). CONCLUSION: The results suggest that high concentrations of 
      endogenous heparin in association with high IgE concentrations and their negative 
      influence on thrombinogenesis, may act as a marker for a favourable prognosis in 
      patients with MI.
FAU - Wladyslaw, Sinkiewicz
AU  - Wladyslaw S
AD  - Intensive Cardiology Care Department, Clinic of Allergology and Internal 
      Diseases, Medical University, Bydgoszcz, Poland. bizkard@by.onet.pl
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Coron Artery Dis
JT  - Coronary artery disease
JID - 9011445
RN  - 0 (Biomarkers)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Protective Agents)
RN  - 0 (antithrombin III-protease complex)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9000-94-6 (Antithrombin III)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Peptide Hydrolases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antithrombin III/drug effects
MH  - Biomarkers/blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolytic Agents/blood/*therapeutic use
MH  - Heparin/blood/*therapeutic use
MH  - Humans
MH  - Immunoglobulin E/blood/drug effects
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*drug therapy
MH  - Peptide Hydrolases/blood/drug effects
MH  - Protective Agents/metabolism/*therapeutic use
MH  - Statistics as Topic
MH  - Treatment Outcome
EDAT- 2003/01/25 04:00
MHDA- 2003/05/16 05:00
CRDT- 2003/01/25 04:00
PHST- 2003/01/25 04:00 [pubmed]
PHST- 2003/05/16 05:00 [medline]
PHST- 2003/01/25 04:00 [entrez]
AID - 10.1097/00019501-200212000-00007 [doi]
PST - ppublish
SO  - Coron Artery Dis. 2002 Dec;13(8):423-6. doi: 10.1097/00019501-200212000-00007.